Considering these changes in genetic testing practices, we re-examined the utility of a clinical history–based approach for classification of BRCA1/BRCA2 VUS in a cohort of >170,000 individuals undergoing hereditary cancer MGPT to develop prediction models that in turn allow inferences to be made about individual variants that can be included in multifactorial classification models. The gene discussed is BRCA1; the disease is hereditary cancer.